{"doi":"10.1192\/02-538","coreId":"208157","oai":"oai:eprints.lse.ac.uk:18120","identifiers":["oai:eprints.lse.ac.uk:18120","10.1192\/02-538"],"title":"Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK","authors":["Duggan, Andy","Warner, Juliet","Knapp, Martin","Kerwin, Robert"],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2003-06","abstract":"Background: Schizophrenia is a major cause of suicide, and symptoms characteristic of treatment-resistant disease are strong risk factors. Clozapine reduces symptoms in 60% of such patients and significantly decreases the risk of suicide.\\ud\n\\ud\nAims: To model the impact of increased clozapine prescribing on lives saved and resource utilisation.\\ud\n\\ud\nMethod: A model was built to compare current levels of clozapine prescribing with a scenario in which all suitable patients with treatment-resistant schizophrenia received clozapine.\\ud\n\\ud\nResults: It was estimated that an average of 53 lives could be saved in the UK each year. If clozapine is cost-neutral, the cost per life-year saved is \u00a35108. If clozapine achieves a 10% reduction in annual support costs, the net saving is \u00a38.7 million per annum. An average of 167 acute beds would be freed each year.\\ud\n\\ud\nConclusions: The use of clozapine in treatment-resistant schizophrenia saves lives, frees resources and is cost-effective","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Royal College of Psychiatrists","rawRecordXml":"<record><header><identifier>\n    \n    \n      oai:eprints.lse.ac.uk:18120<\/identifier><datestamp>\n      2012-05-30T08:47:15Z<\/datestamp><setSpec>\n      74797065733D4445505453:4C53452D5341<\/setSpec><setSpec>\n      74797065733D43454E54524553:4C53455F52435F3536<\/setSpec><setSpec>\n      74797065733D43454E54524553:4C53455F52435F3839<\/setSpec><setSpec>\n      74797065733D43454E54524553:4C53455F52435F4E53534352<\/setSpec><\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:relation>\n    \n      \n        http:\/\/eprints.lse.ac.uk\/18120\/<\/dc:relation><dc:title>\n        Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK<\/dc:title><dc:creator>\n        Duggan, Andy<\/dc:creator><dc:creator>\n        Warner, Juliet<\/dc:creator><dc:creator>\n        Knapp, Martin<\/dc:creator><dc:creator>\n        Kerwin, Robert<\/dc:creator><dc:subject>\n        R Medicine (General)<\/dc:subject><dc:subject>\n        RM Therapeutics. Pharmacology<\/dc:subject><dc:description>\n        Background: Schizophrenia is a major cause of suicide, and symptoms characteristic of treatment-resistant disease are strong risk factors. Clozapine reduces symptoms in 60% of such patients and significantly decreases the risk of suicide.\\ud\n\\ud\nAims: To model the impact of increased clozapine prescribing on lives saved and resource utilisation.\\ud\n\\ud\nMethod: A model was built to compare current levels of clozapine prescribing with a scenario in which all suitable patients with treatment-resistant schizophrenia received clozapine.\\ud\n\\ud\nResults: It was estimated that an average of 53 lives could be saved in the UK each year. If clozapine is cost-neutral, the cost per life-year saved is \u00a35108. If clozapine achieves a 10% reduction in annual support costs, the net saving is \u00a38.7 million per annum. An average of 167 acute beds would be freed each year.\\ud\n\\ud\nConclusions: The use of clozapine in treatment-resistant schizophrenia saves lives, frees resources and is cost-effective.<\/dc:description><dc:publisher>\n        Royal College of Psychiatrists<\/dc:publisher><dc:date>\n        2003-06<\/dc:date><dc:type>\n        Article<\/dc:type><dc:type>\n        PeerReviewed<\/dc:type><dc:identifier>\n          Duggan, Andy and Warner, Juliet and Knapp, Martin and Kerwin, Robert  (2003) Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK.  British Journal of Psychiatry, 182 (6).  pp. 505-508.  ISSN 0007-1250     <\/dc:identifier><dc:relation>\n        http:\/\/bjp.rcpsych.org<\/dc:relation><dc:relation>\n        10.1192\/02-538<\/dc:relation><\/oai_dc:dc><\/metadata><\/record>","journals":null,"language":null,"relations":["http:\/\/eprints.lse.ac.uk\/18120\/","http:\/\/bjp.rcpsych.org","10.1192\/02-538"],"year":2003,"topics":["R Medicine (General)","RM Therapeutics. Pharmacology"],"subject":["Article","PeerReviewed"],"fullText":null}